190 related articles for article (PubMed ID: 32285437)
1. Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target.
Kok Y; Nicolopoulos J; Varigos G; Howard A; Dolianitis C
Australas J Dermatol; 2020 Aug; 61(3):e373-e374. PubMed ID: 32285437
[No Abstract] [Full Text] [Related]
2. PASH syndrome with bony destruction.
McCarthy S; Foley CC; Dvorakova V; Quinlan C; Murphy M; Maher M
Clin Exp Dermatol; 2019 Dec; 44(8):918-920. PubMed ID: 30666706
[No Abstract] [Full Text] [Related]
3. Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline.
Gul MI; Singam V; Hanson C; Neill BC; Aires DJ; Rajpara AN
J Drugs Dermatol; 2020 Nov; 19(11):1123. PubMed ID: 33196740
[No Abstract] [Full Text] [Related]
4. PASH syndrome associated with osteopoikilosis.
Gracia-Cazaña T; Frias M; Roselló R; Vera-Álvarez J; Gilaberte Y
Int J Dermatol; 2015 Sep; 54(9):e369-71. PubMed ID: 26175185
[No Abstract] [Full Text] [Related]
5. Pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) and polycystic ovary syndrome: Coincidentally or aetiologically connected?
Zivanovic D; Masirevic I; Ruzicka T; Braun-Falco M; Nikolic M
Australas J Dermatol; 2017 May; 58(2):e54-e59. PubMed ID: 26831949
[TBL] [Abstract][Full Text] [Related]
6. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.
Bruzzese V
J Clin Rheumatol; 2012 Dec; 18(8):413-5. PubMed ID: 23188209
[TBL] [Abstract][Full Text] [Related]
7. Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients.
Join-Lambert O; Duchatelet S; Delage M; Miskinyte S; Coignard H; Lemarchand N; Alemy-Carreau M; Lortholary O; Nassif X; Hovnanian A; Nassif A
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S66-9. PubMed ID: 26470620
[TBL] [Abstract][Full Text] [Related]
8. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.
Saraceno R; Babino G; Chiricozzi A; Zangrilli A; Chimenti S
J Am Acad Dermatol; 2015 Jan; 72(1):e42-4. PubMed ID: 25497954
[No Abstract] [Full Text] [Related]
9. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab.
De Wet J; Jordaan HF; Kannenberg SM; Tod B; Glanzmann B; Visser WI
Dermatol Online J; 2017 Dec; 23(12):. PubMed ID: 29447652
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier.
Jennings L; Molloy O; Quinlan C; Kelly G; O'Kane M
Int J Dermatol; 2017 Jun; 56(6):e128-e129. PubMed ID: 28239847
[No Abstract] [Full Text] [Related]
11. Successful use of adalimumab to treat pyoderma gangrenosum, acne and suppurative hidradenitis (PASH syndrome) following colectomy in ulcerative colitis.
Murphy B; Morrison G; Podmore P
Int J Colorectal Dis; 2015 Aug; 30(8):1139-40. PubMed ID: 25564349
[No Abstract] [Full Text] [Related]
12. PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity.
Sonbol H; Duchatelet S; Miskinyte S; Bonsang B; Hovnanian A; Misery L
Br J Dermatol; 2018 Jan; 178(1):e17-e18. PubMed ID: 28626985
[No Abstract] [Full Text] [Related]
13. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen.
Shenefelt PD
Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710
[TBL] [Abstract][Full Text] [Related]
14. Pyoderma gangrenosum, acne, hidradenitis suppurativa syndrome associated with type 1 diabetes mellitus treated with adalimumab.
Fattore D; Pistone G; Bongiorno MR
G Ital Dermatol Venereol; 2019 Apr; 154(2):218-220. PubMed ID: 29368847
[No Abstract] [Full Text] [Related]
15. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
Vinkel C; Thomsen SF
Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab for PASS syndrome: A new choice for therapeutic challenge?
Li M; Xiang H; Liang Y; Xue L; Zhou X; Yang L; Liu H; Yang M; Tang J; Li W
Dermatol Ther; 2022 Jul; 35(7):e15507. PubMed ID: 35419914
[TBL] [Abstract][Full Text] [Related]
17. Genetic mutations in pyoderma gangrenosum, hidradenitis suppurativa, and associated autoinflammatory syndromes: Insights into pathogenic mechanisms and shared pathways.
Satoh TK
J Dermatol; 2024 Feb; 51(2):160-171. PubMed ID: 38031879
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone.
Staub J; Pfannschmidt N; Strohal R; Braun-Falco M; Lohse P; Goerdt S; Leverkus M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2243-7. PubMed ID: 25352307
[TBL] [Abstract][Full Text] [Related]
19. PsAPASH: a rare and recent autoinflammatory syndrome associated with hidradenitis suppurativa.
Gadelha RL; Paiva RDSR; Palitot EB; Costa JEFD
An Bras Dermatol; 2020; 95(2):203-206. PubMed ID: 32063421
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of PASS syndrome with IVIG and anti-IL-1 treatment: A case report.
Kırmızıer G; Kılınç EA; Yıldırım NO; Türsen Ü
Int J Rheum Dis; 2024 Mar; 27(3):e15114. PubMed ID: 38465508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
